As reported by PharmaBiz, Zydus Lifesciences has announced the launch of Revahale (revefenacin), a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company says the product is the first therapy in India to combine a LAMA with a once-daily nebulized delivery format.
The introduction of Revahale expands treatment choices for COPD patients who may not be well suited to conventional inhaler-based therapies. The medication is administered through standard jet nebulizers and is intended to provide bronchodilation throughout a 24-hour period after a single daily dose.
COPD has placed a considerable burden on healthcare systems in India, contributing significantly to illness and mortality. Although inhaled bronchodilators remain a cornerstone of disease management, many patients face challenges using handheld inhalers effectively. These difficulties are particularly common among older adults, individuals with cognitive or physical limitations, and patients with advanced disease who struggle to generate sufficient inspiratory flow.
According to Zydus, Revahale was developed to address these challenges by offering a nebulized treatment option that is less dependent on patient inhalation technique. The approach may simplify drug administration for both patients and caregivers while improving accessibility for those unable to use inhalers effectively.
Revefenacin is a lung-targeted bronchodilator designed for long-lasting airway relaxation and symptom control. Clinical studies have shown that the therapy can produce meaningful and lasting results in lung function among patients with moderate-to-very-severe COPD. Reported data also indicate a favorable safety and tolerability profile.
By combining once-daily dosing, compatibility with commonly used nebulizer systems, and prolonged bronchodilatory activity, Revahale represents a new maintenance therapy option for COPD management in India, particularly for patients requiring nebulized treatment.
